A Phase 3 interventional study of Calcipotriol plus hydrocortisone (LEO 80190) and LEO 80190 Vehicle in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 3rd largest by enrollment, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 15th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,245 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 3rd largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2008, is one of 20 in phase 3, and was the 11th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous areas (= double-blind phase). Furthermore, the safety and efficacy will be evaluated for up to 60 weeks treatment as required of calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ointment in psoriasis vulgaris on the face and intertriginous areas (= open-label phase).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)
Drug: Calcipotriol plus hydrocortisone (LEO 80190)
Ointment Vehicle
Drug: LEO 80190 Vehicle
Calcipotriol 25 mcg/g in the ointment vehicle
Drug: Calcipotriol
Hydrocortisone 10 mg/g in the ointment vehicle
Drug: Hydrocortisone
Drug pages: Calcipotriene · Hydrocortisone
Once daily application
Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase
The (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below. Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit. For subjects with a baseline (Visit 1) severity of moderate or worse - "controlled disease" of the face was defined as clear or almost clear according to the IGA of disease severity of the face. For subjects with a baseline (Visit 1) severity of mild - "controlled disease" of the face was defined as clear according to the IGA of disease severity of the face.
Time frame: At Week 8 (end of treatment for double-blind phase)
Participants With "Controlled Disease" According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase
The assessment of the disease severity of the face was made using the 6-category scale below. Clear Almost clear Mild Moderate Severe Very severe The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit. For subjects with a baseline severity of moderate or worse - "controlled disease" of the face was defined as clear or almost clear according to the IGA of disease severity of the face. For subjects with a baseline severity of mild - "controlled disease" of the face was defined as clear according to the IGA of disease severity of the face.
Time frame: At Week 4
Participants With "Success" According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase
"Success" was defined as a TSS score of 0 or 1. For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below: Redness 0 = none (no erythema) 1 = mild (faint erythema, pink to very light red) 2 = moderate (definite light red erythema) 3 = severe (dark red erythema) 4 = very severe (very dark red erythema) Thickness 0 = none (no plaque elevation) 1 = mild (slight, barely perceptible elevation) 2 = moderate (definite elevation but not thick) 3 = severe (definite elevation, thick plaque with sharp edge) 4 = very severe (very thick plaque with sharp edge) Scaliness 0 = none (no scaling) 1 = mild (sparse, fine-scale lesions, only partially covered) 2 = moderate (coarser scales, most of lesions covered) 3 = severe (entire lesion covered with coarse scales) 4 = very severe (very thick coarse scales, possibly fissured) The sum of the three scores constituted a TSS ranging from 0 to 12
Time frame: At Week 8 (end of treatment for double-blind phase)
Participants With "Controlled Disease" According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase
The (sub)investigator made an assessment of the disease severity of the intertriginous areas using the 6-category scale below. Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the intertrigi-nous areas at the time of the evaluation, not in relation to the condition at a previous visit. For subjects with a baseline severity of moderate or worse - "controlled disease" of the intertriginous areas was defined as clear or almost clear according to the IGA of disease severity of the intertriginous areas. For subjects with a baseline severity of mild - "controlled disease" of the intertriginous areas was defined as clear according to the IGA of disease severity of the intertriginous areas.
Time frame: At Week 8 (end of treatment for double-blind phase)
Participants With "Success" According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase
The severity of the subject's psoriasis vulgaris on the intertriginous areas was evaluated in terms of the three clinical signs: redness, thickness and scaliness. All the defined intertriginous areas were rated separately using the same scale as for the investigator's assessment of clinical signs (redness, thickness and scaliness) of the face. For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below: Redness 0 = none 1. = mild 2. = moderate 3. = severe 4. = very severe Thickness 0 = none 1. = mild 2. = moderate 3. = severe 4. = very severe Scaliness 0 = none 1. = mild 2. = moderate 3. = severe 4. = very severe A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS. "Success" was defined as a TSS score of 0 or 1.
Time frame: At Week 8 (end of treatment for double-blind phase)
A total of 1245 subjects were enrolled (informed consent signed and CRF started). Five subjects left the study during washout (2 screening failures, 2 lost to follow-up and 1 unacceptable adverse event). One subject attended Visit 1 but was not randomized (voluntary withdrawal). Therefore, 1239 of the enrolled subjects were randomized in the study.
| Milestone | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Open-label Phase |
|---|---|---|---|---|---|
| Started | 353 | 342 | 363 | 181 | 0 |
| Completed | 325 | 308 | 340 | 169 | 0 |
| Not completed | 28 | 34 | 23 | 12 | 0 |
| Milestone | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Open-label Phase |
|---|---|---|---|---|---|
| Started | 454 | 0 | 0 | 0 | 0 |
| Completed | 403 | 0 | 0 | 0 | 0 |
| Not completed | 51 | 0 | 0 | 0 | 0 |
The (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below. Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit. For subjects with a baseline (Visit 1) severity of moderate or worse - "controlled disease" of the face was defined as clear or almost clear according to the IGA of disease severity of the face. For subjects with a baseline (Visit 1) severity of mild - "controlled disease" of the face was defined as clear according to the IGA of disease severity of the face.
| Participants | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle |
|---|---|---|---|---|
| Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase | 158 | 135 | 115 | 41 |
The assessment of the disease severity of the face was made using the 6-category scale below. Clear Almost clear Mild Moderate Severe Very severe The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit. For subjects with a baseline severity of moderate or worse - "controlled disease" of the face was defined as clear or almost clear according to the IGA of disease severity of the face. For subjects with a baseline severity of mild - "controlled disease" of the face was defined as clear according to the IGA of disease severity of the face.
| Participants | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle |
|---|---|---|---|---|
| Participants With "Controlled Disease" According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase | 101 | 66 | 61 | 14 |
"Success" was defined as a TSS score of 0 or 1. For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below: Redness 0 = none (no erythema) 1 = mild (faint erythema, pink to very light red) 2 = moderate (definite light red erythema) 3 = severe (dark red erythema) 4 = very severe (very dark red erythema) Thickness 0 = none (no plaque elevation) 1 = mild (slight, barely perceptible elevation) 2 = moderate (definite elevation but not thick) 3 = severe (definite elevation, thick plaque with sharp edge) 4 = very severe (very thick plaque with sharp edge) Scaliness 0 = none (no scaling) 1 = mild (sparse, fine-scale lesions, only partially covered) 2 = moderate (coarser scales, most of lesions covered) 3 = severe (entire lesion covered with coarse scales) 4 = very severe (very thick coarse scales, possibly fissured) The sum of the three scores constituted a TSS ranging from 0 to 12
| Participants | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle |
|---|---|---|---|---|
| Participants With "Success" According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase | 171 | 136 | 131 | 42 |
The (sub)investigator made an assessment of the disease severity of the intertriginous areas using the 6-category scale below. Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the intertrigi-nous areas at the time of the evaluation, not in relation to the condition at a previous visit. For subjects with a baseline severity of moderate or worse - "controlled disease" of the intertriginous areas was defined as clear or almost clear according to the IGA of disease severity of the intertriginous areas. For subjects with a baseline severity of mild - "controlled disease" of the intertriginous areas was defined as clear according to the IGA of disease severity of the intertriginous areas.
| Participants | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle |
|---|---|---|---|---|
| Participants With "Controlled Disease" According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase | 80 | 55 | 48 | 14 |
The severity of the subject's psoriasis vulgaris on the intertriginous areas was evaluated in terms of the three clinical signs: redness, thickness and scaliness. All the defined intertriginous areas were rated separately using the same scale as for the investigator's assessment of clinical signs (redness, thickness and scaliness) of the face. For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below: Redness 0 = none 1. = mild 2. = moderate 3. = severe 4. = very severe Thickness 0 = none 1. = mild 2. = moderate 3. = severe 4. = very severe Scaliness 0 = none 1. = mild 2. = moderate 3. = severe 4. = very severe A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS. "Success" was defined as a TSS score of 0 or 1.
| Participants | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle |
|---|---|---|---|---|
| Participants With "Success" According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase | 82 | 81 | 59 | 15 |
Collected over Double-blind Phase: From baseline (Day 0) to end of trial (Day 56±2) + Follow-up (Day 14±2) Open-label Phase: From Week 8 to Week 60 ±7 days + Follow-up (Day 14±2). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LEO 80190 | 0/351 (0%) | 5/351 (1.4%) | 91/351 (25.9%) |
| Calcipotriol | 0/341 (0%) | 5/341 (1.5%) | 100/341 (29.3%) |
| Hydrocortisone | 0/362 (0%) | 4/362 (1.1%) | 70/362 (19.3%) |
| LEO 80190 Vehicle | 0/181 (0%) | 0/181 (0%) | 47/181 (26%) |
| Open-label Phase | 0/453 (0%) | 24/453 (5.3%) | 266/453 (58.7%) |
| Event | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Open-label Phase |
|---|---|---|---|---|---|
| PsoriasisSkin and subcutaneous tissue disorders | 2/351 | 0/341 | 2/362 | 0/181 | 3/453 |
| ErysipelasInfections and infestations | 0/351 | 0/341 | 0/362 | 0/181 | 2/453 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/351 | 0/341 | 0/362 | 0/181 | 2/453 |
| ContusionInjury, poisoning and procedural complications | 0/351 | 0/341 | 0/362 | 0/181 | 2/453 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/351 | 0/341 | 0/362 | 0/181 | 2/453 |
| Atrial fibrillationCardiac disorders | 0/351 | 1/341 | 0/362 | 0/181 | 0/453 |
| PneumoniaInfections and infestations | 0/351 | 1/341 | 0/362 | 0/181 | 1/453 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/351 | 1/341 | 0/362 | 0/181 | 0/453 |
| Benign bone neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/351 | 1/341 | 0/362 | 0/181 | 1/453 |
| Laryngeal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/351 | 1/341 | 0/362 | 0/181 | 0/453 |
| Event | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Open-label Phase |
|---|---|---|---|---|---|
| PsoriasisSkin and subcutaneous tissue disorders | 26/351 | 23/341 | 27/362 | 12/181 | 114/453 |
| NasopharyngitisInfections and infestations | 8/351 | 5/341 | 12/362 | 11/181 | 55/453 |
| ErythemaSkin and subcutaneous tissue disorders | 7/351 | 24/341 | 7/362 | 7/181 | 13/453 |
| PruritusSkin and subcutaneous tissue disorders | 7/351 | 14/341 | 3/362 | 5/181 | 8/453 |
| HeadacheNervous system disorders | 11/351 | 6/341 | 8/362 | 2/181 | 17/453 |
| Burning sensationNervous system disorders | 5/351 | 12/341 | 1/362 | 4/181 | 0/453 |
| RhinitisRespiratory, thoracic and mediastinal disorders | 4/351 | 1/341 | 4/362 | 0/181 | 13/453 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/351 | 0/341 | 0/362 | 0/181 | 12/453 |
| InfluenzaInfections and infestations | 3/351 | 2/341 | 2/362 | 2/181 | 10/453 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/351 | 0/341 | 0/362 | 0/181 | 10/453 |
| Age, Continuous(years) | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 42.8 ± 15.3 | 44.8 ± 15.1 | 43.0 ± 14.1 | 44.6 ± 15.1 | 43.6 ± 14.9 |
| Sex: Female, Male(Participants) | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Total |
|---|---|---|---|---|---|
| Female | 155 | 139 | 147 | 76 | 517 |
| Male | 198 | 203 | 216 | 105 | 722 |
| Region of Enrollment(participants) | LEO 80190 | Calcipotriol | Hydrocortisone | LEO 80190 Vehicle | Total |
|---|---|---|---|---|---|
| Belgium | 4 | 6 | 5 | 2 | 17 |
| Croatia | 15 | 13 | 16 | 7 | 51 |
| Czechia | 29 | 22 | 24 | 15 | 90 |
| Germany | 99 | 95 | 96 | 55 | 345 |
| Hungary | 58 | 59 | 64 | 35 | 216 |
| Latvia | 23 | 20 | 24 | 10 | 77 |
| Macedonia | 7 | 8 | 8 | 3 | 26 |
| Netherlands | 4 | 6 | 5 | 1 | 16 |
| Poland | 79 | 76 | 80 | 37 | 272 |
| Serbia | 34 | 36 | 40 | 16 | 126 |
| Slovenia | 1 | 1 | 1 | 0 | 3 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of May 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2021, 11 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Hydrocortisone